在癌症中向蛋白质降解:PROTACs,新目标和临床机制
Bushra Faryal1, Zain Ul Abideen2, Muhammad Irfan2
1Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Biomolecules
|February 27, 2026
概括
针对蛋白质分解的嵌合体 (PROTACs) 提供了一种新的方式来降解引起疾病的蛋白质,包括以前无法治疗的点. 这种催化方法对克服癌症耐药性和改进精确瘤治疗有希望.
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
- 药物发现 药物发现 药物发现
背景情况:
- 蛋白质解析向嵌合体 (PROTACs) 代表了向癌症治疗的范式转变,超越了传统的占用驱动抑制.
- 这种异构功能技术利用无素-蛋白酶系统 (UPS) 通过E3无素酶招募选择性降解致病蛋白质.
研究的目的:
- 审查PROTAC设计的最新进展,涵盖E3结合酶选择,链接器化学和结合体优化.
- 突出有希望的临床前和临床PROTAC候选人,针对关键的致癌驱动因素和抵抗机制.
- 检查转化挑战,并探索在精密瘤学中用于PROTACs的新兴解决方案.
主要方法:
- 对PROTAC技术和应用的最新创新进行文献综述.
- 分析PROTAC设计原则,包括E3结合酶选择和链接器策略.
- 对PROTAC候选药物的临床前和临床数据的评估,并讨论未来的方法.
主要成果:
- PROTACs可以以催化方式降解蛋白质,包括以前"不可抗药"的标,如转录因子,在亚静态度剂量下.
- 有希望的候选人正在出现对抗致癌驱动因素,抗亡因子 (BCL-xL) 和核激素受体.
- 正在探索AUTAC/ATTEC,LYTAC和人工智能驱动的设计等新的方法来应对翻译挑战.
结论:
- PROTACs为向癌症治疗提供了一个强大而灵活的框架,克服了传统抑制剂的局限性.
- 解决药理动力学,脱效应和耐药性方面的挑战对于临床转化至关重要.
- PROTACs准备重新定义精确瘤学,提供一个可扩展和强大的治疗策略.
相关概念视频
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Protein Networks
4.6K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.6K
Regulated Protein Degradation
3.3K
3.3K
Regulated Protein Degradation
9.1K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
9.1K
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
The Proteasome
1.9K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.9K


